A Phase 2 interventional study of GDC-0853 and Placebo in Urticaria, sponsored by Genentech, Inc.. Completed at 27 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-29.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.
Among the 47 studies in Urticaria with a site in United States, this one is the 10th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 2, and was the 30th registered.
148 studies on the registry are indexed under Urticaria; 19 are open to participants now.
Browse Urticaria studies →4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Pfizer · Sites in United States, Bulgaria, Canada and 7 more countries
Ages 18+
Foundation For Rare Disease Research · Sites in United States
Ages 12–75 · Healthy volunteers
Columbia University · Sites in United States
Ages up to 99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 6 · Phase 4 3
First in 1976; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 51 across 104 interventional studies indexed under Urticaria.
Median enrollment 39 across the 37 interventional studies, 83 across the 10 observational. Of the 39 that completed or were terminated, 21 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
Hoffmann-La Roche has 4 studies filed under Urticaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Urticaria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT06210698Foundation For Rare Disease ResearchAngioedema Biomarker Research Study | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo twice daily from Day 1 to 56.
Drug: Placebo
Participants received GDC-0853 200mg twice daily from Day 1 to 56.
Drug: GDC-0853
Participants received matching placebo up to twice daily from Day 1 to 56.
Drug: Placebo
Participants received GDC-0853 50mg once daily from Day 1 to 56.
Drug: GDC-0853
Participants received GDC-0853 150mg once daily from Day 1 to 56.
Drug: GDC-0853
Participants received GDC-0853 200mg twice daily from Day 1 to 56.
Drug: GDC-0853
GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
Matching Placebo will be administered orally, as per the dosing schedules described above.
Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 57 score minus Baseline score) indicates improvement.
Time frame: Baseline and Day 57
Percentage of Participants Who Are Well-Controlled (UAS7 ≤ 6)
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. Participants with UAS7 score ≤6 are considered well controlled.
Time frame: Day 57
Change From Baseline in the UAS7 at Day 29
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 29 score minus Baseline score) indicates improvement.
Time frame: Baseline and Day 29
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
Time frame: Baseline up until 4 weeks after the last dose of study drug (up to 2 years, 5 months).
Plasma Concentrations of Fenebrutinib (GDC-0853) at Specified Timepoints
Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented. Please note that the Placebo Cohorts were not evaluated for this Outcome Measure.
Time frame: Days 1, 8 and 57.
The study was conducted at 21 centers in 3 countries.
| Milestone | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| Started | 13 | 28 | 23 | 23 | 24 | 23 |
| Completed | 12 | 22 | 20 | 17 | 22 | 21 |
| Not completed | 1 | 6 | 3 | 6 | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 2 | 2 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 3 | 1 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Data entry error | 0 | 0 | 0 | 1 | 0 | 0 |
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 57 score minus Baseline score) indicates improvement.
| Score on a Scale | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 | -19.16 ± 13.49 | -24.05 ± 9.74 | -11.25 ± 10.81 | -15.69 ± 14.25 | -17.05 ± 10.19 | -21.80 ± 14.80 |
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. Participants with UAS7 score ≤6 are considered well controlled.
| Percentage of Participants | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Are Well-Controlled (UAS7 ≤ 6) | 30.8 | 57.1 | 21.7 | 34.8 | 45.8 | 56.5 |
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (Day 29 score minus Baseline score) indicates improvement.
| Score on a Scale | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in the UAS7 at Day 29 | -9.69 ± 10.70 | -22.15 ± 10.33 | -9.05 ± 9.82 | -16.97 ± 14.31 | -13.75 ± 12.93 | -21.69 ± 16.22 |
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.
| Percentage of Participants | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 61.5 | 71.4 | 54.5 | 60.9 | 66.7 | 58.3 |
Plasma Concentration Data for fenebrutinib (GDC-0853) will be tabulated and summarised by visits. Descriptive summary statistics for Arithmetic Mean and Standard Deviation will be presented. Please note that the Placebo Cohorts were not evaluated for this Outcome Measure.
| ng/mL | Cohort 1: GDC-0853 200mg BID | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|
| Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 8 | 378 ± 389 | 38.5 ± 36.9 | 178 ± 237 | 424 ± 385 |
| Day 57 | 283 ± 315 | 19.6 ± 26.3 | 24.7 ± 17.7 | 219 ± 293 |
Collected over Baseline up until 4 weeks after the last dose of study drug (up to 2 years, 5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Placebo | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Cohort 1: GDC-0853 200mg BID | 0/28 (0%) | 3/28 (10.7%) | 16/28 (57.1%) |
| Cohort 2: Placebo | 0/22 (0%) | 0/22 (0%) | 7/22 (31.8%) |
| Cohort 2: GDC-0853 50mg QD | 0/23 (0%) | 0/23 (0%) | 7/23 (30.4%) |
| Cohort 2: GDC-0853 150mg QD | 0/24 (0%) | 0/24 (0%) | 13/24 (54.2%) |
| Cohort 2: GDC-0853 200mg BID | 0/24 (0%) | 0/24 (0%) | 12/24 (50%) |
| Event | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/13 | 1/28 | 0/22 | 0/23 | 0/24 | 0/24 |
| PERIORBITAL CELLULITISInfections and infestations | 0/13 | 1/28 | 0/22 | 0/23 | 0/24 | 0/24 |
| HEPATIC ENZYME INCREASEDInvestigations | 0/13 | 1/28 | 0/22 | 0/23 | 0/24 | 0/24 |
| Event | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID |
|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 3/13 | 7/28 | 1/22 | 3/23 | 3/24 | 3/24 |
| HEADACHENervous system disorders | 3/13 | 4/28 | 2/22 | 0/23 | 1/24 | 3/24 |
| URTICARIASkin and subcutaneous tissue disorders | 0/13 | 5/28 | 2/22 | 3/23 | 4/24 | 5/24 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/13 | 2/28 | 0/22 | 0/23 | 1/24 | 3/24 |
| DIARRHOEAGastrointestinal disorders | 0/13 | 1/28 | 2/22 | 0/23 | 1/24 | 0/24 |
| FATIGUEGeneral disorders | 0/13 | 1/28 | 2/22 | 0/23 | 1/24 | 0/24 |
| NAUSEAGastrointestinal disorders | 0/13 | 2/28 | 0/22 | 1/23 | 2/24 | 2/24 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/13 | 1/28 | 1/22 | 0/23 | 0/24 | 2/24 |
| URINARY TRACT INFECTIONInfections and infestations | 0/13 | 0/28 | 0/22 | 1/23 | 2/24 | 1/24 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 0/13 | 2/28 | 0/22 | 0/23 | 1/24 | 2/24 |
| Age, Continuous(Years) | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 43.6 ± 11.0 | 41.3 ± 15.9 | 40.2 ± 14.7 | 45.0 ± 13.1 | 43.3 ± 16.7 | 44.3 ± 13.0 | 42.8 ± 14.4 |
| Sex: Female, Male(Participants) | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 11 | 22 | 17 | 18 | 20 | 16 | 104 |
| Male | 2 | 6 | 6 | 5 | 4 | 7 | 30 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 5 | 2 | 5 | 2 | 15 |
| Not Hispanic or Latino | 13 | 27 | 16 | 21 | 19 | 20 | 116 |
| Not Stated | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Unknown | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Placebo | Cohort 1: GDC-0853 200mg BID | Cohort 2: Placebo | Cohort 2: GDC-0853 50mg QD | Cohort 2: GDC-0853 150mg QD | Cohort 2: GDC-0853 200mg BID | Total |
|---|---|---|---|---|---|---|---|
| Asian | 0 | 3 | 4 | 3 | 1 | 4 | 15 |
| Black or African American | 1 | 1 | 1 | 1 | 0 | 2 | 6 |
| White | 10 | 24 | 18 | 19 | 23 | 16 | 110 |
| Multiple | 2 | 0 | 0 | 0 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from May 2017 to primary completion in Sep 2019, 28 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 13 phase 2 interventional studies under Urticaria, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenebrutinib